Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 169-175

  Bacher, Ulrike ^a   Haferlach, Torsten ^b   Kern, Wolfgang ^b   Alpermann, Tamara ^b   Schnittger, Susanne ^b   Haferlach, Claudia ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN HEAVY CHAIN; SYNDECAN 1;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL SELECTION; CELL STRUCTURE; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; IMMUNOPHENOTYPING; INTERPHASE; MAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CELL SEPARATION; CHROMOSOME DELETION; CYTOGENETIC ANALYSIS; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MODELS, GENETIC; MULTIPLE MYELOMA; PARAPROTEINEMIAS; SYNDECAN-1;

EID: 78650023344     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.006     Document Type: Article

References (38)

1. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F., Offord J.R., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362-1369.
2. Landgren O., Katzmann J.A., Hsing A.W., Pfeiffer R.M., Kyle R.A., Yeboah E.D., et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007, 82:1468-1473.
3. Iwanaga M., Tagawa M., Tsukasaki K., Kamihira S., Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007, 82:1474-1479.
4. Landgren O., Weiss B.M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009, 23:1691-1697.
5. Blade J., Rosinol L., Cibeira M.T., de Larrea C.F. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008, 22:1651-1657.
6. Swerdlow S., Campo E., Lee Harris N., Jaffe E., Pileri S., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, WHO Press, Lyon. 4th ed.
7. Palumbo A., Sezer O., Kyle R., Miguel J.S., Orlowski R.Z., Moreau P., et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009, 23:1716-1730.
8. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
9. Wuilleme S., Robillard N., Lode L., Magrangeas F., Beris H., Harousseau J.L., et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005, 19:275-278.
10. Chng W.J., Santana-Davila R., Van Wier S.A., Ahmann G.J., Jalal S.M., Bergsagel P.L., et al. Prognostic factors for hyperdiploid-myeloma: effects of hromosome 13 deletions and IgH translocations. Leukemia 2006, 20:807-813.
11. Stewart A.K., Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn 2007, 7:453-459.
12. Reece D., Song K.W., Fu T., Roland B., Chang H., Horsman D.E., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114:522-525.
13. Wu K.L., Beverloo B., Velthuizen S.J., Sonneveld P. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression. Clin Lymphoma Myeloma 2007, 7:280-285.
14. Landgren O., Kyle R.A., Pfeiffer R.M., Katzmann J.A., Caporaso N.E., Hayes R.B., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
15. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
16. Fonseca R., Blood E.A., Oken M.M., Kyle R.A., Dewald G.W., Bailey R.J., et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
17. Brousseau M., Leleu X., Gerard J., Gastinne T., Godon A., Genevieve F., et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res 2007, 13:6026-6031.
18. Nilsson T., Lenhoff S., Rylander L., Hoglund M., Turesson I., Mitelman F., et al. High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation. Br J Haematol 2004, 126:487-494.
19. Bernasconi P., Cavigliano P.M., Boni M., Astori C., Calatroni S., Giardini I., et al. Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance. Br J Haematol 2002, 118:545-549.
20. Avet-Loiseau H., Li J.Y., Morineau N., Facon T., Brigaudeau C., Harousseau J.L., et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 1999, 94:2583-2589.
21. Chiecchio L., Dagrada G.P., Ibrahim A.H., Dachs C.E., Protheroe R.K., Stockley D.M., et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009, 94:1708-1713.
22. Fonseca R., Bailey R.J., Ahmann G.J., Rajkumar S.V., Hoyer J.D., Lust J.A., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002, 100:1417-1424.
23. Rasillo A., Tabernero M.D., Sanchez M.L., Perez de A.M., Martin A.M., Hernandez J., et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer 2003, 97:601-609.
24. Zhou Y., Barlogie B., Shaughnessy J.D. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009, 23:1941-1956.
25. Shaughnessy J.D., Zhan F., Burington B.E., Huang Y., Colla S., Hanamura I., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
26. Avet-Loiseau H., Li C., Magrangeas F., Gouraud W., Charbonnel C., Harousseau J.L., et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009, 27:4585-4590.
27. Rawstron A.C., Orfao A., Beksac M., Bezdickova L., Brooimans R.A., Bumbea H., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438.
28. Craig F.E., Foon K.A. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008, 111:3941-3967.
29. Smock K.J., Perkins S.L., Bahler D.W. Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med 2007, 131:951-955.
30. Nadav L., Katz B.Z., Baron S., Yossipov L., Polliack A., Deutsch V., et al. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol 2006, 133:530-532.
31. Perez-Persona E., Vidriales M.B., Mateo G., Garcia-Sanz R., Mateos M.V., de Coca A.G., et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
32. Mateo G., Montalban M.A., Vidriales M.B., Lahuerta J.J., Mateos M.V., Gutierrez N., et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008, 26:2737-2744.
33. Lust J.A., Donovan K.A. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control 1998, 5:209-217.
34. Rajkumar S.V. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009, 15:5606-5608.
35. Golombick T., Diamond T.H., Badmaev V., Manoharan A., Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 2009, 15:5917-5922.
36. Christensen J.H., Abildgaard N., Plesner T., Nibe A., Nielsen O., Sorensen A.G., et al. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet 2007, 15:89-99.
37. Sagaster V., Ludwig H., Kaufmann H., Odelga V., Zojer N., Ackermann J., et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007, 21:164-168.
38. Harousseau J.L., Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(suppl 4):97-99.